Search

Your search keyword '"Kocsis, Judit"' showing total 194 results
Start Over Author "Kocsis, Judit"
194 results on '"Kocsis, Judit"'

1. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

Author

Choueiri, Toni K, Zakharia, Yousef, Pal, Sumanta, Kocsis, Judit, Pachynski, Russell, Poprach, Alexandr, Nixon, Andrew B, Liu, Yingmiao, Starr, Mark, Lyu, Jing, Owzar, Kouros, deShazo, Mollie, Lara, Primo, Geczi, Lajos, Ho, Thai H, Walsh, Meghara, Adams, Bonne, Robertson, Liz, Darif, Mohamed, Theuer, Charles, and Agarwal, Neeraj

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Cancer, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, 5.1 Pharmaceuticals, Antibodies, Monoclonal, Axitinib, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Vascular Endothelial Growth Factor A, Phase II, TRAXAR, Renal cell cancer, Endoglin, TRC105, Carotuximab, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Lessons learnedThe combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)-targeted therapies. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels.BackgroundEndoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors.MethodsTRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 RESULTS: A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels.ConclusionThe combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.

Published
2021

2. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Author

Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto, Yao, James, García-Alfonso, Pilar, Kocsis, Judit, Cubillo Gracian, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Paulson, Andrew Scott, Masuishi, Toshiki, Jones, Jeremy, Csőszi, Tibor, Cremolini, Chiara, Ghiringhelli, Francois, Shergill, Ardaman, Hochster, Howard S, Krauss, John, Bassam, Ali, Ducreux, Michel, Elme, Anneli, Faugeras, Laurence, Kasper, Stefan, Van Cutsem, Eric, Arnold, Dirk, Nanda, Shivani, Yang, Zhao, Schelman, William R, Kania, Marek, Tabernero, Josep, and Eng, Cathy

Published
2023
Full Text
View/download PDF

3. Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study.

Author

Lonardi, Sara, Dasari, Arvind, Tabernero, Josep, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto F., Yao, James C., Garcia-Alfonso, Pilar, Kocsis, Judit, Cubillo Gracian, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Paulson, Andrew Scott, Wu, Liwen, Chen, Lucy F., and Eng, Cathy

Published
2025
Full Text
View/download PDF

4. Validation of the Hungarian Version of the International Consultation on Incontinence Modular Questionnaire on Female Lower Urinary Tract Symptoms (ICIQ-FLUTS).

Author

Debes, Wesam A., Sadaqa, Munseef, Makai, Alexandra, Dózsa-Juhász, Olívia, Tumpek, Nikolett, Kocsis, Judit, Ács, Pongrác, Szűcs, Réka Laura, Németh, Zsanett, Prémusz, Viktória, and Hock, Marta

Subjects
URINARY incontinence, URINARY organs, TEST validity, INTRACLASS correlation, PSYCHOMETRICS
Abstract

Objectives: Urinary incontinence (UI) is a prevalent condition that significantly impacts the quality of life. This study aimed to validate the Hungarian version of the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) and assess its psychometric properties in the context of the Hungarian population. Study design: A cross-sectional study involved 215 Hungarian-speaking women with a mean age of 67.6 ± 11.9 years. Main outcome measure: Participants were administered both the ICIQ-FLUTS and the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF). The psychometric analysis included test–retest reliability, convergent validity, and internal consistency. Results: The Hungarian version of ICIQ-FLUTS demonstrated strong psychometric properties. The test–retest reliability analysis showed a high intraclass correlation coefficient (ICC = 0.921), indicating excellent agreement between measurements over a 14-day interval. Convergent validity was supported by a strong positive correlation between the total scores of ICIQ-FLUTS and ICIQ-SF (ρ = 0.686, p < 0.001), emphasizing shared underlying constructs. Furthermore, the ICIQ-FLUTS questionnaire exhibited good internal consistency, with a Cronbach's α coefficient of 0.862. Conclusions: This study successfully validated the Hungarian version of the ICIQ-FLUTS questionnaire and demonstrated its robust psychometric properties. This tool will enable healthcare practitioners and researchers to effectively assess and address UI's impact on their quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer.

Author

Boér, Katalin, Kaposi, Ambrus, Kocsis, Judit, Horváth, Zsolt, Madaras, Balázs, Sávolt, Ákos, Klément, Gyorgy Benjamin, and Rubovszky, Gábor

Subjects
POSTOPERATIVE care, CONSENSUS (Social sciences), CANCER relapse, RESEARCH funding, BREAST tumors, EARLY detection of cancer, LOGISTIC regression analysis, DECISION making, DESCRIPTIVE statistics, ADJUVANT chemotherapy, PRE-tests & post-tests, STATISTICS, ONCOLOGISTS, DATA analysis software, INTER-observer reliability
Abstract

Simple Summary: Postoperative adjuvant chemotherapy generally improves survival in patients with breast cancer. However, adjuvant chemotherapy does not benefit all patients. There are considerations and guidelines that guide us as to whether or not chemotherapy is recommended to a particular patient. The decision is based on clinicopathologic features and may be aided by multigene assays. The Oncotype DX test is used worldwide. It makes the recommendation more accurate; however, there are possibilities to refine the process to make a more accurate decision. We investigated how we could move forward in recommending adjuvant chemotherapy. Background: The use of the Oncotype DX test reduces the rate of adjuvant chemotherapy recommendations. Few in-depth analyses have been performed on this decision-making process. Methods: We retrospectively analyzed patient data based on available Oncotype DX test results (RS) irrespective of nodal status at a single center. We collected recommendations from six oncologists, first without RS (pre-RS) and then with RS results (post-RS). We investigated changes in recommendations, agreement between oncologist decisions, and the effect of different National Comprehensive Cancer Network (NCCN) recommendation categories (for, against, and considering chemotherapy). Results: Data from 201 patients were included in the analysis. Recommendation of chemotherapy decreased by an average of 39.5%. Agreement improved substantially with RS, with a kappa value pre-RS of 0.37 (fair agreement) and post-RS of 0.75 (substantial agreement). Discordance remained substantial in cases where the NCCN recommendations considered chemotherapy only (32%). Pre-RS consensus against chemotherapy predicted low RS results (50 out of 51 patients). Post-RS consensus was highest in the NCCN chemotherapy recommendation group. Conclusions: The Oncotype DX test substantially improves decision accuracy in recommending adjuvant chemotherapy. It may be further improved with a consensus decision. In the case of pre-RS consensus against chemotherapy, the test can be spared. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

8. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Author

Acosta-Rivera, Mirelis, Adkins, Douglas R., Aghmesheh, Morteza, Ahn, Myung-Ju, Airoldi, Mario, Aleknavicius, Eduardas, Al-Farhat, Yousuf, Algazi, Alain P., Almokadem, Salah, Alyasova, Anna, Bauman, Jessica R., Benasso, Marco, Berrocal, Alfonso, Bray, Victoria, Burtness, Barbara Ann, Caponigro, Francesco, Castro, Ana, Cescon, Terrence P., Chan, Kelvin, Chaudhry, Arvind, Chauffert, Bruno, Cohen, Ezra, Csoszi, Tibor, De Boer, J.P., Delord, Jean-Pierre, Dietz, Andreas, Dinis, Jose, Dupuis, Charlotte, Digue, Laurence, Erfan, Jozsef, Escobar Alvarez, Yolanda, Evans, Mererid, Fidler, Mary Jo, Forster, Martin David, Friesland, Signe, Ganti, Apar K., Geoffrois, Lionnel, Grant, Cliona, Gruenwald, Viktor, Harrington, Kevin, Hoffmann, Thomas, Horvai, Geza, Inciura, Arturas, Jang, Raymond, Jankowska, Petra, Jimeno, Antonio, Joseph, Mano, Juarez Ramiro, Alejandro, Karaszewska, Boguslawa, Kawecki, Andrzej, Keilholz, Ulrich, Keller, Ulrich, Kim, Sung-Bae, Kocsis, Judit, Kotecki, Nuria, Kozloff, Mark F., Lambea, Julio, Landherr, Laszlo, Lantsukhay, Yuri, Lazarev, Sergey Alexandrovich, Lee, Lip Way, Le Tourneau, Christophe, Licitra, Lisa, Lifirenko, Igor Dmitrievich, Mach, Nicolas, Martincic, Danko, Matorin, Oleg Vladmirovhich, McGrath, Margaret, Machiels, Jean-Pascal, Mehra, Ranee, Misiukiewicz, Krzysztof, Morris, John C., Mufazalov, Fagim Fanisovich, Niu, Jiaxin, Pamoorthy Srinivasan, Devraj, Perez Segura, Pedro, Rauch, Daniel, Ribeiro, Maria Leonor, Rodriguez, Cristina, Rolland, Frederic, Russo, Antonio, Ruzsa, Agnes, Sanches, Frederico, Shin, Sang-Won, Shtiveland, Mikhail, Soulieres, Denis, Soria, Ainara, Specenier, Pol, Szekanecz, Eva, Szota, Judit, van Herpen, Carla M.L., Velez-Cortes, Hector A., Walsh, William V., Wilop, Stefan, Winterhalder, Ralph, Wojtukiewicz, Marek, Wong, Deborah, Zandberg, Dan, Cohen, Ezra E W, Soulières, Denis, Dinis, José, Burtness, Barbara, Zhang, Pingye, Cheng, Jonathan, Swaby, Ramona F, and Harrington, Kevin J

Published
2019
Full Text
View/download PDF

12. Opposite trends in incidence of breast cancer in young and old female cohorts in Hungary and the impact of the Covid-19 pandemic: a nationwide study between 2011–2020

Author

Kiss, Zoltán, primary, Kocsis, Judit, additional, Nikolényi, Alíz, additional, Horváth, Zsolt, additional, Knollmajer, Kata, additional, Benedek, Angéla, additional, Várnai, Máté, additional, Polányi, Zoltán, additional, Kovács, Krisztina Andrea, additional, Berta, Andrea, additional, Köveskuti, István, additional, Karamousouli, Eugenia, additional, Szabó, Tamás Géza, additional, Rokszin, György, additional, Fábián, Ibolya, additional, Bartókné Tamás, Renáta, additional, Surján, Orsolya, additional, Fürtős, Diána, additional, Surján, György, additional, Kenessey, István, additional, Weber, András, additional, Barcza, Zsófia, additional, Berki, Tamás, additional, Vokó, Zoltán, additional, Dózsa, Csaba, additional, Dank, Magdolna, additional, and Boér, Katalin, additional

Published
2023
Full Text
View/download PDF

13. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

18. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy

Author

Lódi, Mária, Priksz, Dániel, Fülöp, Gábor Áron, Bódi, Beáta, Gyöngyösi, Alexandra, Nagy, Lilla, Kovács, Árpád, Kertész, Attila Béla, Kocsis, Judit, Édes, István, Csanádi, Zoltán, Czuriga, István, Kisvárday, Zoltán, Juhász, Béla, Lekli, István, Bai, Péter, Tóth, Attila, Papp, Zoltán, and Czuriga, Dániel

Published
2019
Full Text
View/download PDF

19. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Author

Bardia, Aditya, primary, Bidard, Francois-Clement, additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, Jose Angel, additional, Bria, Emilio, additional, Cazzaniga, Marina Elena, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Tonini, Giulia, additional, Sahmoud, Tarek, additional, Habboubi, Nassir, additional, Grzegorzewski, Krzysztof, additional, and Kaklamani, Virginia, additional

Published
2023
Full Text
View/download PDF

21. Áttétes vesedaganatos betegek kabozantinibterápiájának multicentrikus magyarországi eredményei

Author

Maráz Anikó, Nagyiványi Krisztián, Balogh Ingrid, Bodoky György, Mangel László Csaba, Küronya Zsófia, Géczi Lajos, Torday László, Dudás Szilvia, Szűcs Miklós, Nagy Zsófia, Hornyák Lajos, Zolcsák Zita, Bassam Ali, Kocsis Judit, Keresztes Tamás, Kullmann Tamás, Máhr Károly, Solymosi Tibor, Papdán Tímea, Szabó Imre, Varga Zoltán, and Biró Krisztina

Subjects
03.02. Klinikai orvostan
Abstract

The aim of our analysis was to evaluate the efficacy of cabozantinib in patients with metastatic renal cell carcinoma. Cabozantinib therapy initiated between 01/01/2019 and 31/12/2022 was evaluated based on a retrospective review of data from 14 renal centers in Hungary. The starting dose was 60 or 40 mg. Physical examinations and laboratory tests were performed every 4 weeks and imaging studies 3-monthly. Tumor response was assessed according to RECIST 1.1, and toxicity according to NCI CTCAE 4.0. A total of 230 patient records were evaluated, 201 (87.4%) of them had clear cell RCC. Cabozantinib was administered as third, second and first-line treatment in 48.7%, 38.3% and

Published
2023

22. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

Author

Sobrero, Alberto F., primary, Dasari, Arvind, additional, Lonardi, Sara, additional, Garcia-Carbonero, Rocio, additional, Elez, Elena, additional, Yoshino, Takayuki, additional, Yao, James C., additional, Garcia-Alfonso, Pilar, additional, Kocsis, Judit, additional, Cubillo, Antonio, additional, Sartore-Bianchi, Andrea, additional, Satoh, Taroh, additional, Randrian, Violaine, additional, Tomasek, Jiri, additional, Chong, Geoff, additional, Yang, Zhao, additional, Schelman, William R., additional, Kania, Marek K., additional, Tabernero, Josep, additional, and Eng, Cathy, additional

Published
2023
Full Text
View/download PDF

23. Corrigendum: Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer

Author

Rubovszky, Gábor, primary, Kocsis, Judit, additional, Boér, Katalin, additional, Chilingirova, Nataliya, additional, Dank, Magdolna, additional, Kahán, Zsuzsanna, additional, Kaidarova, Dilyara, additional, Kövér, Erika, additional, Krakovská, Bibiana Vertáková, additional, Máhr, Károly, additional, Mriňáková, Bela, additional, Pikó, Béla, additional, Božović-Spasojević, Ivana, additional, and Horváth, Zsolt, additional

Published
2023
Full Text
View/download PDF

27. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, Francois-Clement, primary, Kaklamani, Virginia G., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick M., additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García Sáenz, José A., additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Liu, Shubin, additional, Tonini, Giulia, additional, Laurent, Dirk, additional, Habboubi, Nassir, additional, Conlan, Maureen G., additional, and Bardia, Aditya, additional

Published
2022
Full Text
View/download PDF

28. Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer

Author

Rubovszky Gabor, Kocsis Judit, Boer Katalin, Chilingirova Nataliya, Dank Magdolna, Kahan Zsuzsanna, Kaidarova Dilyara, Kover Erika, Vertakova Krakovska Bibiana, Mahr Karoly, Piko Bela, Boožović-Spasojević Ivana, Horvath Zsolt, and Central-Eastern European Academy of Oncology (CEEAO) International Professional Panel

Subjects
adjuvant tratment, neoadjuvant treatment, Cancer Research, locally advanced breast cancer, Oncology, adjuvant treatment, General Medicine, metastatic breast cancer, early breast cancer, inflammatory breast cancer, guideline, Pathology and Forensic Medicine
Abstract

This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified based on the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The professional guideline primarily reflects the resolutions and recommendations of the current ESMO, NCCN and ABC5, as well as that of the St. Gallen Consensus Conference statements. The recommendations cover classical prognostic factors and certain multigene tests, which play an important role in therapeutic decision-making. From a didactic point of view, the text first addresses early and then locally advanced breast cancer, followed by locoregionally recurrent and metastatic breast cancer. Within these, we discuss each group according to the available therapeutic options. At the end of the recommendations, we summarize the criteria for treatment in certain rare clinical situations., FUNDING The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Ráth Gy. u 7-9 Correspondence: Gábor Rubovszky, moc.liamg@gykzsvobur † These authors have contributed equally to this work and share first authorship

Published
2022

30. CATALYSTS OF CHANGE: ADVANCING EQUITY IN HUNGARIAN EDUCATION.

Author

BOGNÁRNÉ KOCSIS, Judit

Subjects
ALTERNATIVE schools, ELEMENTARY schools
Abstract

In 1945 a regulation was made, with the commitment to establish a universally compulsory eight-year elementary school system in Hungary. At that time, only two notable experimental schools existed. One is associated with the name of László Gáspár, exemplified by the school experiment in Szentlőrinc (1969). The second is the Linguistic-Literary-Communication Programme (1971), and - stemming from this-the Value Transmitting and Ability Development Programme developed by József Zsolnai. The objective of this research is to elucidate the pedagogical approacches of József Zsolnai and László Gáspár with a specific focus on disadvantaged situations, the principles underlying their programs and equal opportunities. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer

Author

Rubovszky, Gábor, primary, Kocsis, Judit, additional, Boér, Katalin, additional, Chilingirova, Nataliya, additional, Dank, Magdolna, additional, Kahán, Zsuzsanna, additional, Kaidarova, Dilyara, additional, Kövér, Erika, additional, Krakovská, Bibiana Vertáková, additional, Máhr, Károly, additional, Mriňáková, Bela, additional, Pikó, Béla, additional, Božović-Spasojević, Ivana, additional, and Horváth, Zsolt, additional

Published
2022
Full Text
View/download PDF

32. Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

Author

Kaklamani, Virginia G., primary, Bardia, Aditya, additional, Aftimos, Philippe Georges, additional, Cortes, Javier, additional, Lu, Janice M., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joohyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen Kiernan, additional, Khong, Hung T., additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick Michael, additional, Tonini, Giulia, additional, Grzegorzewski, Kris, additional, and Bidard, François-Clement, additional

Published
2022
Full Text
View/download PDF

36. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable mutations. Patients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; = .002) and patients with mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; = .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively). Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

37. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

PURPOSE Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies.METHODSThis randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations.RESULTSPatients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P =.002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P =.0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively).CONCLUSIONElacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

38. Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Author

Bardia, Aditya, primary, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Vuylsteke, Peter, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Kaklamani, Virginia, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, José, additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortes, Javier, additional, Liu, Shubin, additional, Laurent, Dirk, additional, Conlan, Maureen G., additional, and Bidard, Francois-Clement, additional

Published
2022
Full Text
View/download PDF

41. Analysis of Low Cancer Mortality Rates in the Wine Regions of Tokaj and Balaton in Hungary

Author

Sipka, Sándor, Nagy, János, Sipka, Péter, Kocsis, Judit, Tóth, Judit, Árkosy, Péter, and Horváth, Zsolt

Subjects
Aged, 80 and over, Hungary, Drinking Water, lcsh:R, food and beverages, lcsh:Medicine, Wine, Article, age-adjusted death rate, wines of Balaton, Socioeconomic Factors, Hardness, Neoplasms, Humans, cancer, Aged, wines of Tokaj
Abstract

The age-adjusted death rates (AADRs) due to cancers were investigated in two historical regions of white wines (Tokaj and Balaton) and in H&oacute, dmezőv&aacute, s&aacute, rhely (HMV) as a control territory in Hungary between 2000 and 2010 evaluating 111,910 persons. The results of AADRs due to the eight most frequent types/gastrointestinal cancers were as follows: Tokaj 2120/664, Balaton: 2417/824, HMV: 2770/821, nationwide: 2773/887. The values found in Tokaj and Balaton regions were significantly less than those of HMV and nationwide. However, the least values were found in Tokaj. This Tokaj-related strong difference was not found among the regions in the case of young populations with hematological diseases but only in the older people who have been consuming their wines for decades. Supposedly, this wine-specific anti-cancer phenomenon could be related to the chemical differences existing in the two types of white wines, namely, to the pro-oxidant molecules of Tokaj wines derived from Botrytis cinerea. The roles of red meat consumption, hardness of drinking water, mineral content of soil, and socioeconomic status were negligible. It should be stressed that these data are valid only for these populations, for this period. Noteworthily, the different types of wines may have different effects on mortality rates during long-lasting consumptions.

Published
2020

44. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Author

Tannir, Nizar M., primary, Signoretti, Sabina, additional, Choueiri, Toni K., additional, McDermott, David F., additional, Motzer, Robert J., additional, Flaifel, Abdallah, additional, Pignon, Jean-Christophe, additional, Ficial, Miriam, additional, Frontera, Osvaldo Arén, additional, George, Saby, additional, Powles, Thomas, additional, Donskov, Frede, additional, Harrison, Michael R., additional, Barthélémy, Philippe, additional, Tykodi, Scott S., additional, Kocsis, Judit, additional, Ravaud, Alain, additional, Rodriguez-Cid, Jeronimo R., additional, Pal, Sumanta K., additional, Murad, Andre M., additional, Ishii, Yuko, additional, Saggi, Shruti Shally, additional, McHenry, M. Brent, additional, and Rini, Brian I., additional

Published
2021
Full Text
View/download PDF

46. The Hardness of Drinking Water Negatively while Socio-Economic Deprivation Positively Correlate with the Age-Adjusted Mortality Rates due to Cardiovascular Diseases in Hungarian Wine Regions

Author

Nagy, János, Sipka, Sándor, Kocsis, Judit, and Horváth, Zsolt

Subjects
Hungary, index of deprivation, Drinking Water, lcsh:R, white wine, food and beverages, lcsh:Medicine, Wine, red wine, water hardness, Article, cardiovascular diseases, age-adjusted death rate, Socioeconomic Factors, Hardness, Humans
Abstract

We compared the age-adjusted death rates (AADR) for cardiovascular diseases (CVD) among 206,159 inhabitants analyzed between 2000 and 2010 in four wine territories of Hungary: Tokaj (white wines), Eger (mostly red wines), Balaton (mostly white wines), Szekszárd-Villány (mostly red wines) and Hódmezővásárhely (HMV) (not a wine region). The mortality rates were also assessed from the aspects of total hardness of drinking water and index of socio-economic deprivation (ID). We found the highest cardiovascular mortality in the Tokaj region and HMV. On the other hand, lower numbers of CVD were observed in Szekszárd-Villány, Balaton and Eger. These findings on cardiovascular mortality correlated negatively and significantly with the values of total hardness of drinking waters, which were low in Tokaj and HMV. They were higher in Szekszárd-Villány, Balaton and Eger. Additionally, and surprisingly, the mortality of CVD correlated positively and significantly with the ID values despite of the small numeric differences. The hardness of drinking water and the level of socio-economic state seem to have a greater impact on the mortality rate of CVD than the consumption of “red” or “white” dominant types of wines at a region. This study shows data on a population larger than 200,000 persons.

Published
2019

48. Karácsony Sándor, a református értékközvetítő neveléstudós

Author

Bognárné Kocsis Judit

Subjects
Faith, Enthusiasm, Work (electrical), Aesthetics, media_common.quotation_subject, Philosophy of life, Sociology, Duty, media_common
Abstract

Sandor Karacsony (1891-1952) is one of the most significant teachers who had a great effect on the reformed education. Transmitting the values of the reformation can be seen both in his public and scientific life, his religion means the essence of his life. His mission is characterized by the union of the reformed faith and creating, which are to glorify God. As Calvin's follower, he feels as a duty to read the Word continuously, to fulfil his tasks in a very high niveau, to deal with his talents consciously and the hard-working and diligent work, for which he gets the spiritual force, the tireless enthusiasm from the religion. He adopted the principles of the universal priesthood, the Word and its credo to the pedagogy According to Karacsony the education should be a common work, a life-community, in which the faith of the educator is of great importance. His life philosophy is determined by the self-education, the improving of the social relationship-culture and it is important to him to work as an important member of the society.

Published
2017
Full Text
View/download PDF

49. MOESM1 of Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy

Author

Lódi, Mária, Priksz, Dániel, Fülöp, Gábor, Bódi, Beáta, Gyöngyösi, Alexandra, Nagy, Lilla, Kovács, Árpád, Kertész, Attila, Kocsis, Judit, Édes, István, Csanádi, Zoltán, Czuriga, István, Kisvárday, Zoltán, Juhász, Béla, Lekli, István, Bai, Péter, Tóth, Attila, Papp, Zoltán, and Czuriga, Dániel

Subjects
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, ComputingMilieux_COMPUTERSANDEDUCATION, Data_FILES, ComputerApplications_COMPUTERSINOTHERSYSTEMS
Abstract

Additional file 1. Online supplementary material.

Published
2019
Full Text
View/download PDF

50. Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck : a randomized clinical trial

Author

Burtness, Barbara, Haddad, Robert, Dinis, Jose, Trigo, Jose, Yokota, Tomoya, de Viana, Luciano Souza, Romanov, Ilya, Vermorken, Jan Baptist, Bourhis, Jean, Tahara, Makoto, Martins Segalla, Jose Getulio, Psyrri, Amanda, Vasilevskaya, Irina, Nangia, Chaitali Singh, Chaves-Conde, Manuel, Kiyota, Naomi, Homma, Akihiro, Holeckova, Petra, Del Campo, Josep Maria, Asarawala, Nirav, Nicolau, Ulisses Ribaldo, Rauch, Daniel, Even, Caroline, Wang, Bushi, Gibson, Neil, Ehrnrooth, Eva, Harrington, Kevin, Cohen, Ezra E. W., Eduardo Giglio, Raul, Raul Blajman, Cesar, Mario Freue, Jose, Graciela Pilnik, Norma, Salvador Palazzo, Felipe, McGrath, Margaret, Fureder, Thorsten, Kornek, Gabriela, Pichler, Angelika, Bauernhofer, Thomas, Tinchon, Christoph, Greil, Richard, Burian, Martin, Kienzer, Heinz, Specenier, Pol, Sautois, Brieuc, Debruyne, Philip, Graas, Marie-Pascale, Maes, Annelies, Lonchay, Christophe, Daisne, Jean-Francois, Fontaine, Christel, Castro Junior, Gilberto, de Oliveira, Frias, Pereira, Rodrigo Perez, Martins De Marchi, Pedro Rafael, Lazaretti, Nicolas Silva, Kulkarni, Swati, Alam, Yasmin, Ho, Cheryl, Shenouda, George, Soulieres, Denis, Sultanem, Khalil, Singh, Simron, Gonzalez Mella, Pablo, Solis Campos, Jose Antonio, Prausova, Jana, Obermannova, Radka, Friborg, Jeppe, Specht, Lena, Elsaid, Amr Abdelaziz, Minn, Heikki, Martin, Laurent, Rolland, Frederic, Ceruse, Philippe, Calais, Gilles, Guigay, Joe, Ferte, Charles, Peyrade, Frederic, Duffaud, Florence, Champeaux-Orange, Elise, Coutte, Alexandre, Clatot, Florian, Fournel, Pierre, Le Moal, Laurence Bozec, Dietz, Andreas, Gruenwald, Viktor, Gauler, Thomas, Guntinas-Lichius, Orlando, Hildebrandt, Guido, Kuhnt, Thomas, Schmidt, Horst-Juergen, Henke, Michael, Rueckert, Anja, Brugger, Wolfram, Rotter, Nicole, Mahlberg, Rolf, Karavasilis, Vasilios, Fountzilas, Georgios, Psyrri, Diamanto, Lang, Istvan, Boer, Andras, Kocsis, Judit, Pajkos, Gabor, Tamas, Laszlo, Anand, A. L., Sharma, Ajay, Sharma, Voona, Murali, Pandy, Ananda Selvakumar, Kumar, Kirushna, Nathan, Raj Kumar Poovna, Srinivasan, Venkatesan, Zade, Bhooshan, Jain, Minish, Srinivasa, B. J., Naik, Radheshyam, Mohanty, B. K., Charas, Tomer, Billan, Salem, Popovtzer, Aron, Licitra, Lisa, Ferrari, Daris, Fao, Paolo, Merlano, Marco, Rocca, Maria Cossu, Fujii, Hirofumi, Minami, Syujiro, Fujii, Masato, Kadowaki, Shigenori, Muro, Kei, Okami, Kenji, Yagi, Toshinari, Yoshino, Kunitoshi, Matsumoto, Koji, Takahashi, Shunji, Matsuura, Kazuto, Alvarez Avitia, Miguel Angel, Gonzalez Riestra, Hector Jorge, van Meerten, E., Buter, J., Gelderblom, A. J., Kawecki, Andrzej, Golusinski, Wojciech, Dinis, Rui, Ribeiro, Leonor, Silva, Regina, Mansinho, Helder, Selezneva, Irina, Biakhov, Mikhail, Galiulin, Rinat, Izmailov, Adel, Vladimirov, Vladimir, Vinogradov, Valery, Mufazalov, Fagim, Baste, Neus, Ma del Campo, Josep, Mesia Nin, Ricard, Lopez Pousa, Antonio, Jose Grau de Castro, Juan, Reig, Oscar, Vera, Ruth, Trigo, JoseManuel, Iglesias, Lara, Martinez Trufero, Javier, Vazquez, Sergio, Rubio, Belen, Enrique Ales, Jose, Villar, Esther, Rubio, Jordi, Escobar, Yolanda, Soria, Ainara, Chaves, Mauel, Johansson, Gun Wickart, Friesland, Signe, Tell, Roger, Nyman, Jan, Rothschild, Sacha, Zippelius, Alfred, Usluoglu, Nurguel, Gogunska, Inna, Zabolotniy, Dmytro, Vinnyk, Yuriy, Burian, Oleksandr, Sykes, Andrew, Peel, David, Lester, James, Robinson, Martin, Srinivasan, Devraj, Fragkandrea-Nixon, Ioanna, Junor, Elizabeth, Gollins, Simon, Evans, Mererid, Newbold, Kate, Hwang, David, Schipani, Stefano, Rizwanullah, Mohammed, Atiq, Omar, Arnaoutakis, Konstantinos, Bauman, Jessica, Mehra, Ranee, Kang, Hyunseok, Chung, Christine, Davis, Thomas, Jimeno, Antonio, Keresztes, Roger, Nangia, Chaitali, Ignatius, Sai-Hong, Su, Yungpo Bernard, Overton, Lindsay Carol, Garrison, Mitchell A., Jeong, Woondong, Wehbe, Ahmad, Argiris, Athanassios, Chiang, Anne, Morgensztern, Daniel, Haigentz, Missak, Jr., Martincic, Danko, Porosnicu, Mercedes, LUX-HEAD & Neck 2 Investigators, Medical Oncology, and Boehringer Ingelheim Fonds

Subjects
Oncology, Cancer Research, medicine.medical_specialty, animal structures, Afatinib, Population, Medizin, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, mental disorders, medicine, Adjuvant therapy, Clinical endpoint, 030212 general & internal medicine, education, 610 Medicine & health, Original Investigation, education.field_of_study, business.industry, food and beverages, medicine.disease, Head and neck squamous-cell carcinoma, 030220 oncology & carcinogenesis, bacteria, sense organs, Human medicine, business, Chemoradiotherapy, medicine.drug
Abstract

LUX-Head & Neck 2 investigators., [Importance] Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC., [Objective] To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC., [Design, Setting, and Participants] This multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 patients from November 2, 2011, to July 4, 2016. Patients who had complete response after CRT, comprising radiotherapy with cisplatin or carboplatin, with or without resection of residual disease, for locoregionally advanced high- or intermediate-risk HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx were included in the study. Data analysis was of the intention-to-treat population., [Interventions] Patients were randomized (2:1) to treatment with afatinib (40 mg/d) or placebo, stratified by nodal status (N0-2a or N2b-3) and Eastern Cooperative Oncology Group performance status (0 or 1). Treatment continued for 18 months or until disease recurrence, unacceptable adverse events, or patient withdrawal., [Main Outcomes and Measures] The primary end point was DFS, defined as time from the date of randomization to the date of tumor recurrence or secondary primary tumor or death from any cause. Secondary end points were DFS at 2 years, overall survival (defined as time from the date of randomization to death), and health-related quality of life., [Results] A total of 617 patients were studied (mean [SD] age, 58 [8.4] years; 528 male [85.6%]). Recruitment was stopped after a preplanned interim futility analysis on July 4, 2016, on recommendation from an independent data monitoring committee. Treatment was discontinued. Median DFS was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57; stratified log-rank test P = .48). The most common grade 3 and 4 drug-related adverse effects were acneiform rash (61 [14.8%] of 411 patients in the afatinib group vs 1 [0.5%] of 206 patients in the placebo group), stomatitis (55 [13.4%] in the afatinib group vs 1 [0.5%] in the placebo group), and diarrhea (32 [7.8%] in the afatinib group vs 1 [0.5%] in the placebo group)., [Conclusions and Relevance] This study’s findings indicate that treatment with afatinib after CRT did not improve DFS and was associated with more adverse events than placebo in patients with primary, unresected, clinically high- to intermediate-risk HNSCC. The use of adjuvant afatinib after CRT is not recommended., [Trial Registration] ClinicalTrials.gov identifier: NCT01345669., The study was funded by Boehringer Ingelheim.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results